Crystec strengthens manufacturing capabilities through partnership with Juniper Pharma Services

Written By Becky Murphy

Aug 14, 2017


The partnership between Crystec and Juniper Pharma Services has reached another key milestone, with Crystec’s commercial scale supercritical fluid rig now on-site at Juniper Pharma Services in Nottingham.

Crystec are delighted to announce that our partnership with Juniper Pharma Services (JPS), a Nottingham based Contract Development and Manufacturing Organisation (CDMO), has reached another key milestone. Crystec’s commercial scale, supercritical fluid (SCF) rig is now on site at JPS and is ready for GMP manufacture.

 This important partnership allows Crystec to further accelerate development timelines, taking products rapidly from concept to feasibility and on to clinical manufacture in months. To read the full press release please click here, and for more information about our particle engineering technology platform please contact Emily Bevis (emily.bevis@crystecpharma.com).

To keep up to date with the latest news from Crystec, please follow us on LinkedIn.

Becky Murphy
Previous

China Resources Pharmaceutical Group and CrystecPharma enter agreement to bridge research and innovation between China and the UK
Next

Crystec have been shortlisted for the RSC Emerging Technologies Competition